圣诺医药-B(2257.HK)正式招股，欲冲刺核酸药物第一股？

花生投资见闻

2021-12-20

疫情下，全球核酸药物市场再次沸腾，港股市场亦迎来RNA药物第一股--圣诺医药-B。圣诺医药是一家专注于RNAi及mRNA药物和疫苗研发创制的国际生物制药公司，在美国和中国均深耕多年且占有重要市场地位。

圣诺医药-B(2257.HK)日前已通过聆讯，并于12月20日启动IPO新股认购，冲刺成为中国核酸药物第一股。圣诺医药如何披荆斩棘乘风破浪，我们一起期待！

IPO情报局

美港股新股第一手情报

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

月野寻兔
2021-12-27
月野寻兔
他的疫苗有什么独到之处吗？
- 花生投资见闻:
  主要是技术储备和未来的预期前景比价好。从招股书看，目前有三方面的进展：药物递送平台；基于RNAi技术的候选药物STP705和STP707；基于mRNA技术的新冠疫苗候选药物。
- 花生投资见闻:
  你查看下视频吧。技术成就、产品进展，里面有介绍的。
山野万里
2021-12-27
山野万里
所以这家企业是美国的吗？
- 花生投资见闻:
  在中国和美国都有运营实体。因为这类生物制药高新技术公司，必须在人才最集中、资金最密集、技术最先进的地区设立研发中心，在供应链配套最完善、人工成本最合适的地区设立生产中心。
长歌灯火时
2021-12-27
长歌灯火时
现在疫情又反复了，市场需求又要上扬了
- 花生投资见闻:
  是的。

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693359886,"tweetId":"693359886","gmtCreate":1639975069484,"gmtModify":1639993770008,"author":{"id":3540336831493404,"idStr":"3540336831493404","authorId":3540336831493404,"authorIdStr":"3540336831493404","name":"花生投资见闻","avatar":"https://static.tigerbbs.com/6db3d41c37f0046811807b60dd2009fd","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":283,"starInvestorFlag":false},"themes":[{"themeId":"0e78c0db8cb445f7b26f2b55e79c0399","categoryId":"7ba93224048e4975aa9a5a60d7f2353b","name":"IPO情报局","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":0e78c0db8cb445f7b26f2b55e79c0399}&rnconfig={\"headerBarHidden\": true}","description":"美港股新股第一手情报","image":"https://static.tigerbbs.com/a3d8508367645ebd59b1152593bbbe56"}],"images":[],"coverImages":[{"img":"https://static.tigerbbs.com/333d7f58ab80ae7b1208ae27e700fa28","width":"0","height":"0"}],"title":"圣诺医药-B(2257.HK)正式招股，欲冲刺核酸药物第一股？","extraTitle":"","html":"<html><head></head><body>\n<video class=\"ql-video\" controls controlslist=\"nodownload\" poster=\"https://static.tigerbbs.com/333d7f58ab80ae7b1208ae27e700fa28\" playsinline=\"true\" webkit-playsinline=\"true\" tg-width=\"1920\" tg-height=\"1080\">\n <source src=\"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/041b2237387702293216687830/a8dz6Rlito4A.mp4\" type=\"video/mp4\">\n</video>疫情下，全球核酸药物市场再次沸腾，港股市场亦迎来RNA药物第一股--圣诺医药-B。圣诺医药是一家专注于RNAi及mRNA药物和疫苗研发创制的国际生物制药公司，在美国和中国均深耕多年且占有重要市场地位。圣诺医药-B(2257.HK)日前已通过聆讯，并于12月20日启动IPO新股认购，冲刺成为中国核酸药物第一股。圣诺医药如何披荆斩棘乘风破浪，我们一起期待！</body></html>","htmlText":"<html><head></head><body>\n<video class=\"ql-video\" controls controlslist=\"nodownload\" poster=\"https://static.tigerbbs.com/333d7f58ab80ae7b1208ae27e700fa28\" playsinline=\"true\" webkit-playsinline=\"true\" tg-width=\"1920\" tg-height=\"1080\">\n <source src=\"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/041b2237387702293216687830/a8dz6Rlito4A.mp4\" type=\"video/mp4\">\n</video>疫情下，全球核酸药物市场再次沸腾，港股市场亦迎来RNA药物第一股--圣诺医药-B。圣诺医药是一家专注于RNAi及mRNA药物和疫苗研发创制的国际生物制药公司，在美国和中国均深耕多年且占有重要市场地位。圣诺医药-B(2257.HK)日前已通过聆讯，并于12月20日启动IPO新股认购，冲刺成为中国核酸药物第一股。圣诺医药如何披荆斩棘乘风破浪，我们一起期待！</body></html>","text":"疫情下，全球核酸药物市场再次沸腾，港股市场亦迎来RNA药物第一股--圣诺医药-B。圣诺医药是一家专注于RNAi及mRNA药物和疫苗研发创制的国际生物制药公司，在美国和中国均深耕多年且占有重要市场地位。 圣诺医药-B(2257.HK)日前已通过聆讯，并于12月20日启动IPO新股认购，冲刺成为中国核酸药物第一股。圣诺医药如何披荆斩棘乘风破浪，我们一起期待！","highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":7,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693359886","repostId":0,"isVote":1,"tweetType":2,"object":{"id":"ffc7dacb00d446e2b028cb3337688ce5","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/041b2237387702293216687830/a8dz6Rlito4A.mp4","poster":"https://static.tigerbbs.com/333d7f58ab80ae7b1208ae27e700fa28","desc":""},"viewCount":12823,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["09939","159938"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":311,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":7112971,"commentId":"7112971","gmtCreate":1640535062126,"gmtModify":1640535062126,"authorId":9000000000000440,"author":{"id":9000000000000440,"idStr":"9000000000000440","authorId":9000000000000440,"name":"月野寻兔","avatar":"https://static.tigerbbs.com/5b57e08f7bdb99e89325f075cf471b98","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693359886,"objectIdStr":"693359886","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"他的疫苗有什么独到之处吗？","text":"他的疫苗有什么独到之处吗？","html":"他的疫苗有什么独到之处吗？","likeSize":0,"commentSize":2,"subComments":[{"id":7158343,"commentId":"7158343","gmtCreate":1641437692408,"gmtModify":1641438145966,"authorId":3540336831493404,"author":{"id":3540336831493404,"idStr":"3540336831493404","authorId":3540336831493404,"name":"花生投资见闻","avatar":"https://static.tigerbbs.com/6db3d41c37f0046811807b60dd2009fd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693359886,"objectIdStr":"693359886","type":1,"supId":7112971,"supIdStr":"7112971","prevId":0,"prevIdStr":"0","content":"主要是技术储备和未来的预期前景比价好。从招股书看，目前有三方面的进展：药物递送平台；基于RNAi技术的候选药物STP705和STP707；基于mRNA技术的新冠疫苗候选药物。","text":"主要是技术储备和未来的预期前景比价好。从招股书看，目前有三方面的进展：药物递送平台；基于RNAi技术的候选药物STP705和STP707；基于mRNA技术的新冠疫苗候选药物。","html":"主要是技术储备和未来的预期前景比价好。从招股书看，目前有三方面的进展：药物递送平台；基于RNAi技术的候选药物STP705和STP707；基于mRNA技术的新冠疫苗候选药物。"},{"id":7158354,"commentId":"7158354","gmtCreate":1641437909935,"gmtModify":1641437909935,"authorId":3540336831493404,"author":{"id":3540336831493404,"idStr":"3540336831493404","authorId":3540336831493404,"name":"花生投资见闻","avatar":"https://static.tigerbbs.com/6db3d41c37f0046811807b60dd2009fd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693359886,"objectIdStr":"693359886","type":1,"supId":7112971,"supIdStr":"7112971","prevId":0,"prevIdStr":"0","content":"你查看下视频吧。技术成就、产品进展，里面有介绍的。","text":"你查看下视频吧。技术成就、产品进展，里面有介绍的。","html":"你查看下视频吧。技术成就、产品进展，里面有介绍的。"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":7112969,"commentId":"7112969","gmtCreate":1640535042648,"gmtModify":1640535042648,"authorId":9000000000000596,"author":{"id":9000000000000596,"idStr":"9000000000000596","authorId":9000000000000596,"name":"山野万里","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693359886,"objectIdStr":"693359886","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"所以这家企业是美国的吗？","text":"所以这家企业是美国的吗？","html":"所以这家企业是美国的吗？","likeSize":0,"commentSize":1,"subComments":[{"id":7158350,"commentId":"7158350","gmtCreate":1641437806896,"gmtModify":1641437806896,"authorId":3540336831493404,"author":{"id":3540336831493404,"idStr":"3540336831493404","authorId":3540336831493404,"name":"花生投资见闻","avatar":"https://static.tigerbbs.com/6db3d41c37f0046811807b60dd2009fd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693359886,"objectIdStr":"693359886","type":1,"supId":7112969,"supIdStr":"7112969","prevId":0,"prevIdStr":"0","content":"在中国和美国都有运营实体。因为这类生物制药高新技术公司，必须在人才最集中、资金最密集、技术最先进的地区设立研发中心，在供应链配套最完善、人工成本最合适的地区设立生产中心。","text":"在中国和美国都有运营实体。因为这类生物制药高新技术公司，必须在人才最集中、资金最密集、技术最先进的地区设立研发中心，在供应链配套最完善、人工成本最合适的地区设立生产中心。","html":"在中国和美国都有运营实体。因为这类生物制药高新技术公司，必须在人才最集中、资金最密集、技术最先进的地区设立研发中心，在供应链配套最完善、人工成本最合适的地区设立生产中心。"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":7112965,"commentId":"7112965","gmtCreate":1640534998033,"gmtModify":1640534998033,"authorId":9000000000000424,"author":{"id":9000000000000424,"idStr":"9000000000000424","authorId":9000000000000424,"name":"长歌灯火时","avatar":"https://static.tigerbbs.com/907cd7c24e0c3693fe01cf437bf1e553","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693359886,"objectIdStr":"693359886","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"现在疫情又反复了，市场需求又要上扬了","text":"现在疫情又反复了，市场需求又要上扬了","html":"现在疫情又反复了，市场需求又要上扬了","likeSize":0,"commentSize":1,"subComments":[{"id":7158352,"commentId":"7158352","gmtCreate":1641437829483,"gmtModify":1641437829483,"authorId":3540336831493404,"author":{"id":3540336831493404,"idStr":"3540336831493404","authorId":3540336831493404,"name":"花生投资见闻","avatar":"https://static.tigerbbs.com/6db3d41c37f0046811807b60dd2009fd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693359886,"objectIdStr":"693359886","type":1,"supId":7112965,"supIdStr":"7112965","prevId":0,"prevIdStr":"0","content":"是的。","text":"是的。","html":"是的。"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693359886"}